企業プロフィール
Repligen 株価・ニュース・カタリスト
- ティッカー:
- RGEN
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
169.04 USD (+1.32%)
終値
最終更新: 2026年8月17日
6.83B USD
時価総額
株価変動の要因
As of Aug 17, 2026, RGEN closed up 1.32% at $169.04. No new same-company headline was identified in the current news window.
企業概要
Bioprocessing Technology Supplier
Repligen is a global life sciences company focused on technologies and systems used in biologic drug manufacturing. Its customers include biopharmaceutical developers and contract development and manufacturing organizations seeking greater efficiency, control, and scalability in production.
Four Core Technology Areas
The company’s portfolio spans Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Together, these technologies address critical steps from upstream through downstream biologic manufacturing.
Consumables and Workflow Integration
Many Repligen products are recurring-use consumables embedded in validated manufacturing processes. This creates durable customer relationships and demand linked to biologic production volumes, process intensification, and capacity expansion.
Biopharma and CDMO Customer Base
Repligen sells to biologic drug developers, commercial manufacturers, and contract development and manufacturing organizations. Its products can be adopted during process development and remain in use as a therapy advances toward larger-scale and commercial production.
Cell Therapy Supply Chain Expansion
Repligen’s planned acquisition of BioLife Solutions is intended to broaden its consumables and systems presence across cell therapy workflows. The transaction represents an expansion of the company’s manufacturing platform and supply-chain capabilities rather than a single-asset development event.
今後のカタリスト
- Repligen’s watchpoints are bioprocess order recovery, new consumable adoption, and any sign that capital spending is loosening. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。